Restoration of acid secretion following treatment with proton pump inhibitors

Gastroenterology

Volumn 123, Issue 5, 2002, Pages 1588-1597

  Shin, Jai Moo ^a   Sachs, George ^a  

^a VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE; DISULFIDE; DITHIOTHREITOL; HISTAMINE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATASE; RABEPRAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BINDING; DRUG EFFECT; DRUG HALF LIFE; DRUG STRUCTURE; ENANTIOMER; ENZYME INHIBITION; ENZYME REACTIVATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN METABOLISM; PROTEIN SYNTHESIS; RAT; STOMACH ACID SECRETION; STRUCTURE ACTIVITY RELATION; TURNOVER TIME;

EID: 0036830257     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2002.36593     Document Type: Article

References (40)

1. Meuwissen SG, Klinkenberg-Knol EC. Management of gastro-oesophageal reflux disease. Are there alternatives to omeprazole? Digestion 1989;44(suppl 1):54-62.
2. + ATPase. Ann Rev Pharmacol Toxicol 1995;35:277-305.
3. Koop H, Hotz J, Pommer G, Klein M, Arnold R. Prospective evaluation of omeprazole treatment in reflux oesophagitis refractory to H2-receptor antagonists. Aliment Pharmacol Ther 1990;4:593-599.
4. Nwokolo CU, Smith JT, Gavey C, Sawyerr A, Pounder RE. Tolerance during 29 days of conventional dosing with cimetidine, nizatidine, famotidine or ranitidine. Aliment Pharmacol Ther 1990;4(suppl 1):29-45.
5. Colin-Jones DG. The role and limitations of H2-receptor antagonists in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1995;9(suppl 1):9-14.
6. Munson K, Lambrecht N, Shin JM, Sachs G. Analysis of the membrane domain of the gastric H(+)/K(+)-ATPase. J Exp Biol 2000;203:161-170.
7. +-adenosine triphosphatase alpha subunit and its effect on inhibition of rat gastric acid secretion. Gastroenterology 1995;109:1134-1141.
8. +)-ATPase in vivo by omeprazole. Biochem Biophys Res Commun 1985;126:78-82.
9. Katashima M, Yamamoto K, Tokuma Y, Hata T, Sawada Y, Iga T. Comparative pharmacokinetic/pharmacodynamic analysis of proton pump inhibitors omeprazole, lansoprazole and pantoprazole, in humans. Eur J Drug Metab Pharmacokinet 1998;23:19-26.
10. Dammann HG, Burkhardt F, Wolf N. The effects of oral rabeprazole on endocrine and gastric secretory function in healthy volunteers. Aliment Pharmacol Ther 1999;13:1195-1203.
11. +-ATPase. Methods Enzymol 1988;157:649-654.
12. +-ATPase membrane. Am J Physiol 1984;246:C537-C545.
13. +)-ATPase. Biochim Biophys Acta 1984;772:167a-175a.
14. +)-ATPase. Biochem Biophys Res Commun 1982;108:635-639.
15. Lambrecht N, Munson K, Vagin O, Sachs G. Comparison of covalent with reversible inhibitor binding sites of the gastric H,K-ATPase by site-directed mutagenesis. J Biol Chem 2000;275:4041-4048.
16. Tomiyama Y, Morii M, Takeguchi N. Specific proton pump inhibitors E3810 and lansoprazole affect the recovery process of gastric secretion in rats differently. Biochem Pharmacol 1994;48:2049-2055.
17. Satoh H, Inatomi N, Nagaya H, Inada I, Nohara A, Nakamura N, Maki Y. Anti-secretory and anti-ulcer activities of a novel proton pump inhibitor AG-1749 in dogs and rats. J Pharmacol Exp Ther 1989;248:806-815.
18. Scott DR, Helander HF, Hersey SJ, Sachs G. The site of acid secretion in the mammalian parietal cell. Biochim Biophys Acta 1993;1146:73-80.
19. Malinowska DH, Sachs G. Cellular mechanisms of acid secretion. Clin Gastroenterol 1984;13:309-326.
20. Lorentzon P, Jackson R, Wallmark B, Sachs G. Inhibition of (H+ + K+)-ATPase by omeprazole in isolated gastric vesicles requires proton transport. Biochim Biophys Acta 1987;897:41-51.
21. Lindberg P, Nordberg P, Alminger T, Brandstrom A, Wallmark B. The mechanism of action of the gastric acid secretion inhibitor omeprazole. J Med Chem 1986;29:1327-1329.
22. Besancon M, Shin JM, Mercier F, Munson K, Miller M, Hersey S, Sachs G. Membrane topology and omeprazole labeling of the gastric HK-adenosine triphosphatase. Biochemistry 1993;32:2345-2355.
23. Sachs G, Shin JM, Besancon M, Prinz C. The continuing development of gastric acid pump inhibitors. Aliment Pharmacol Ther 1993;7:4-12.
24. Shin JM, Besancon M, Simon A, Sachs G. The site of action of pantoprazole in the gastric H/K-ATPase. Biochim Biophys Acta 1993;1148:223-233.
25. Besancon M, Simon A, Sachs G, Shin JM. Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents. J Biol Chem 1997;272:22438-22446.
26. Toyoshima C, Nakasako M, Nomura H, Ogawa H. Crystal structure of the calcium pump of sarcoplasmic reticulum at 2.6 Å resolution. Nature 2000;405:647-655.
27. 2+-ATPase in E1 and E2 states. Biophys J 2001;80:2187-2197.
28. +-independent dephosphorylation and preference for the E1 conformation by combined mutagenesis of transmembrane glutamate residues. J Biol Chem 2001;276:36909-36916.
29. +- ATPase. Biochemistry 2001;40:7480-7490.
30. +)-ATPase by omeprazole. Biochim Biophys Acta 1985;817:25-32.
31. Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Clin Pharmacokinet 1996;31:9-28.
32. Katashima M, Yamamoto K, Sugiura M, Sawada Y, Iga T. Comparative pharmacokinetic/pharmacodynamic study of proton pump inhibitors, omeprazole and lansoprazole in rats. Drug Metab Dispos 1995;23:718-723.
33. +- ATPase activity. J Biol Chem 1985;260:13681-13684.
34. Kromer W, Postius S, Riedle R, Simon WA, Hanauer G, Brand U, Gonne S, Parsons ME. BY 1023/SK&F 96022, pantoprazole, a novel gastric proton pump inhibitor, potently inhibits acid secretion but lacks relevant cytochrome P450 interactions J Exp Pharmacol Ther 1990;254:129-135.
35. Im WB, Blakeman DP, Sachs G. Reversal of anti-secretory activity of omeprazole by sulfhydryl compounds in isolated rabbit gastric glands. Biochim Biophys Acta 1985;845:54-59.
36. Fujisaki H, Shibata H, Oketani K, Murakami M, Fujimoto M, Wakabayashi T, Yamatsu I, Yamaguchi M, Sakai H, Takeguchi N. Inhibition of acid secretion by E3810 and omeprazole, and their reversal by glutathione. Biochem Pharmacol 1991;42:321-328.
37. Prakash A, Faulds D. Rabeprazole. Drugs 1998;55:261-267.
38. Williams MP, Sercombe J, Hamilton MI, Pounder RE. A placebo controlled trial of the effects of 8 days of dosing with rabeprazole Versus omeprazole on 24-hr intragastric acidity and plasma gastrin concentration in healthy young male subjects. Aliment Phamacol Ther 1998;12:1079-1089.
39. Ohning GV, Barbuti RC, Kovacs TO, Sytnik B, Humphries TJ, Walsh JH. Rabeprazole produced rapid, potent and long-acting inhibition of gastric acid secretion in subjects with Helicobacter pylori infection. Aliment Pharmacol Ther 2000;12:701-708.
40. +-ATPase inhibitors, omeprazole and E3810. J Biol Chem 1993;268:21553-21559.